title: Phosphotyrosine protein phosphatases activation by ACTH in rat adrenal gland.
abstract: The steady state level of most cellular phosphoproteins is dependent on the relative catalytic activities of intracellular protein kinases and phosphatases. In adrenal cortex, ACTH acts through PKA activation and Ser/Tre phosphorylation. Phosphatases involved in this pathway are not completely described, particularly the role of phosphotyrosine protein phosphatase (PTP) activity on ACTH action. We investigated potential changes in PTPs activity in adrenal gland upon in vivo and in vitro PKA activation. In vivo ACTH stimulates cytosolic PTP activity (2-fold). Similar effect is detected by in vitro stimulation. In accordance with the effects of ACTH on PTP activity, cell permeable PTP inhibitors block ACTH stimulation on adrenal zona fasciculata (ZF) cells: ACTH (1 nM) = 108.2 +/- 3.5 ng corticosterone/10(5) cells vs. ACTH + phenylarsine oxide (2 nM) = 60 +/- 4 (P < 0.001) and ACTH + pervanadate (10 mM) = 68 +/- 2 (P < 0.01). These results are reproduced when cells are stimulated with cAMP. The inhibition is not observed when steroidogenesis is supported by 22(R)OH cholesterol. We describe, for the first time, a hormonal regulation of PTP activity. According to the effect of PTP inhibitors on steroid production activated by ACTH we propose that PTP activation is a crucial event in hormone action in the steroidogenic pathway. We also propose that PTP activity is located after PKA activation and prior to cholesterol transport to the inner mitochondrial membrane.
authors.affiliation: Department of Biochemistry, School of Medicine, University of Buenos Aires, Argentine.
authors.forename: F
authors.initials: F
authors.lastname: Cornejo Maciel
authors.forename: C
authors.initials: C
authors.lastname: Paz
authors.forename: M I
authors.initials: MI
authors.lastname: Neuman
authors.forename: E J
authors.initials: EJ
authors.lastname: Podestá
mesh_terms: D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology*; D000818:Animals; D001152:Arsenicals / Q000494:pharmacology; D003345:Corticosterone / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D003600:Cytosol / Q000201:enzymology; D004338:Drug Combinations; D004789:Enzyme Activation / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006888:Hydroxycholesterols / Q000494:pharmacology; D051381:Rats; D014638:Vanadates / Q000494:pharmacology; D015383:Zona Fasciculata / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology*
chemical_list: D001152:Arsenicals; D004338:Drug Combinations; D004791:Enzyme Inhibitors; D006888:Hydroxycholesterols; C076715:pervanadate; C029341:oxophenylarsine; C003585:22-hydroxycholesterol; D015124:8-Bromo Cyclic Adenosine Monophosphate; D014638:Vanadates; D000324:Adrenocorticotropic Hormone; D003345:Corticosterone